Ronald E Kates
Overview
Explore the profile of Ronald E Kates including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Richters L, Gluz O, Weber-Lassalle N, Christgen M, Haverkamp H, Kuemmel S, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2461639.
PMID: 40009381
Importance: Subgroup definitions for possible deescalation of neoadjuvant cancer treatment are urgently needed in clinical practice. Objective: To investigate the effect of BRCA1 and/or BRCA2 tumor pathogenic variants (tPVs) by...
2.
Degenhardt T, Fasching P, Luftner D, Muller V, Thomssen C, Schem C, et al.
Trials
. 2023 May;
24(1):338.
PMID: 37198674
Background: Efficacy and quality of life (QoL) are key criteria for therapy selection in metastatic breast cancer (MBC). In hormone receptor positive (HR +) human epidermal growth factor receptor 2...
3.
Gluz O, Nitz U, Christgen M, Kuemmel S, Holtschmidt J, Schumacher J, et al.
JAMA Oncol
. 2023 May;
9(7):946-954.
PMID: 37166817
Importance: Combination of chemotherapy with (dual) ERBB2 blockade is considered standard in hormone receptor (HR)-positive/ERBB2-positive early breast cancer (EBC). Despite some promising data on endocrine therapy (ET) combination with dual...
4.
Nitz U, Gluz O, Kummel S, Christgen M, Braun M, Aktas B, et al.
J Clin Oncol
. 2022 Apr;
40(23):2557-2567.
PMID: 35404683
Purpose: To our knowledge, WSG-ADAPT-HR+/HER2- (ClinicalTrials.gov identifier: NCT01779206; n = 5,625 registered) is the first trial combining the 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine...
5.
Kolberg-Liedtke C, Wuerstlein R, Gluz O, Heitz F, Freudenberger M, Bensmann E, et al.
Breast Care (Basel)
. 2021 Nov;
16(5):475-483.
PMID: 34720807
Introduction: Tumor biological factors of breast cancer (BC) such as hormone receptor (HR) status, HER2 status, and grade can differ in the metastatic cascade from primary to lymph node (LN)...
6.
Wuerstlein R, Harbeck N, Grischke E, Forstmeyer D, von Schumann R, Krabisch P, et al.
Breast Care (Basel)
. 2021 Mar;
16(1):50-58.
PMID: 33716632
Background: Protroca evaluated the efficacy and safety of primary and secondary prophylaxis of neutropenia with lipegfilgrastim (Lonquex®) in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy (CT). Patients And Methods:...
7.
Nitz U, Gluz O, Kreipe H, Christgen M, Kuemmel S, Baehner F, et al.
Ther Adv Med Oncol
. 2020 Dec;
12:1758835920973130.
PMID: 33281950
Background: Endocrine sensitivity, as determined by response of the proliferation marker Ki-67 to short-term preoperative endocrine therapy (ET), is currently not included in adjuvant treatment decisions in hormone receptor (HR)+/human...
8.
Christgen M, Gluz O, Harbeck N, Kates R, Raap M, Christgen H, et al.
Cancer
. 2020 Aug;
126(22):4847-4858.
PMID: 32780421
Background: Invasive lobular breast cancer (BC) is the second most common BC subtype. Prognostic parameters (tumor classification, lymph node status, histologic grade, Oncotype DX recurrence score [RS], progesterone receptor status,...
9.
Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, et al.
J Clin Oncol
. 2019 Feb;
37(10):799-808.
PMID: 30785826
Purpose: The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment of human epidermal growth factor receptor...
10.
Nitz U, Gluz O, Christgen M, Kates R, Clemens M, Malter W, et al.
Breast Cancer Res Treat
. 2019 Jan;
175(1):265-266.
PMID: 30632020
The article Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG)...